Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Phase 2 Study of Copanlisib in Combination With Rituximab and CHOP Chemotherapy (COPA-R-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

NCT04263584 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT04263584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04263584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Phase 2 Study of Copanlisib in Combination With Rituximab and CHOP Chemotherapy (COPA-R-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
Lead sponsor
University Hospital Muenster
Phase
Phase 2
Overall status
Completed
Start date
June 19, 2020
Completion date
May 3, 2025
Enrollment
62 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma